Lobe Sciences Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LOBEF research report →
Companywww.lobesciences.com
Lobe Sciences Ltd. , a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications.
- CEO
- Frederick Dominick Sancilio
- IPO
- 2023
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $19.80M
- P/E
- -6.47
- P/S
- 0.00
- P/B
- 119.50
- EV/EBITDA
- -3.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4099.95%
- ROIC
- -311.75%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-4,424,660 · -0.08%
- EPS
- $-0.03 · 11.88%
- Op Income
- $-4,176,322
- FCF YoY
- -116.31%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.00
- Beta
- 0.27
- Avg Volume
- 93.88K
Get TickerSpark's AI analysis on LOBEF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LOBEF Coverage
We haven't published any research on LOBEF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LOBEF Report →